Robert Don, Discovery & Preclinical Director, Drugs for Neglected Diseases

Dr Robert Don holds overall responsibility for DNDi’s discovery research and preclinical development. Prior to joining DNDi, he was Senior Vice President for Research and Clinical Development at the Australian based biotechnology company, Progen Pharmaceuticals for 10 years. In this position he was responsible the company’s research program to develop new therapeutics for treatment of cancer and guided the development novel anti-cancer agents from basic research to clinical trials in several countries including USA, United Kingdom, Taiwan and Australia. He was awarded his PhD by the University of Queensland in Australia and completed postdoctoral fellowships at the Medical University in Geneva and the New South Wales Cancer Council in Australia followed by a faculty position at the University of Queensland.